More Videos
SPECIAL REPORT
MOST SHARED
- BlackRock: Central Banks To Be Net Buyers of Gold
- Fed Likely to Keep Rates Low Despite Dollar's Fall: Bernanke
- Millions May Have to Repay Part of Obama Tax Credit
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- Underwater Mortgages Could Sink Even Deeper
- Gold Is in a 'Bubble' And Will Keep Going Higher: Gartman
- Weak US Housing Market Drags on Lowe's Profit
- Cisco Ups Tandberg Bid, Claims Over 40% Backing
- Madoff Auction: $4,750 for a Decoy Duck?
- Snoop Dogg Talks Biz
- Paulson Funds Report Q3 Performance
- Warren Buffett's Berkshire Portfolio Snapshot Coming Later Today
- 'Blood and Business Don't Mix' — A Family Business Survival Guide
- Mixed Signals Come From Retail Sector as Holidays Draw Near
- Will the S&P 500 Close Above 1100?
- What Were The Northwest Pilots Really Doing?
- Your Jobless Recovery Game Plan
- S&P to Hit 1,175 in the Short Term: Strategist
- Fed to Keep Rates Low Despite Dollar's Fall: Bernanke
- Millions Could Have to Repay Part of Obama's Tax Credit
- Fed's Fisher: Government Debt Could Push Rates Higher
- What Recovery? Many Homeowners Still Underwater
- Gold Is in a 'Bubble' And Will Keep Going Higher: Gartman
- Diamonds: The Next Big Bubble to Burst?
- Slideshow: Madoff's Luxury Boats Go Up for Auction
- Solar Energy Emerges From a Dark Period
- How Much Do You Know About Green?
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
The FDA giveth and the FDA taketh away.
Yesterday the agency handed Merck [MRK
Loading...
()
] a little bit of a break with what could be interpreted as an endorsement, of sorts, of the cholesterol drug Vytorin that MRK shares with Schering-Plough [SGP
Loading...
()
]. Although financially, the pill is more important to SGP than it is to MRK.
But then this morning the Dow component announced that the FDA has issued another delay in deciding whether to approve the company's Gardasil vaccine for sexually transmitted disease and cervical cancer for older women. The agency wants more data which Merck says won't be ready to turn over to regulators until the fourth quarter of this year.
Gardasil is approved for females nine to 26 years old. MRK wants permission to also sell it to women between the ages of 27 and 45 who the company says remain at risk for HPV- (Human Papillomavirus) related disease "throughout their lifetimes."
In addition, late last month Merck filed for FDA approval of the vaccine for males between the ages of nine and 26. Guys carry and transmit HPV. Both of those populations could help MRK spur Gardasil sales growth which has slowed over the past year or so. It's a blockbuster product and had been a new, key growth driver.
Nonetheless, Merck is reconfirming that it will still post overall 2009 sales of $23.7-$24.2 billion. And it isn't touching its earnings guidance either. However, the press release says, "The Company will update other elements of its 2009 guidance on its February 3, 2009 earnings conference call." I'm guessing that it might have to revise its 2009 Gardasil sales estimate of $1.4-$1.6 billion.
I'm off to San Francisco for the JPMorgan [JPM
Loading...
()
] Healthcare Conference. I'll be reporting from there on Tuesday, all day long, with live interviews of nine executives representing a cross-section of the industry. Merck Chairman and CEO Dick Clark is not one of them.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes